Resources Repository
-
ArticlePublication 2024Disparities in TB Incidence by Race & Ethnicity Among the U.S.-Born Population in the U.S., 2011 to 2021
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born …
This study aims to assess trends in racial/ethnic disparities in tuberculosis (TB) incidence among U.S.-born individuals from 2011 to 2021. Using national TB registry data, time-series analysis was conducted, stratifying by race/ethnicity and adjusting for age, year, and state of residence. Results indicate persistent disparities, with incidence rate ratios as high as 14.2 for American Indian or Alaska Native (AI/AN) females compared to non-Hispanic White individuals. Relative disparities were more pronounced for females, younger individuals,…
North America | Chronic Disease/Risk | Infectious Diseases | Health/Medicine -
ArticlePublication 2022Early HPV Natural History Transitions
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on …
Microsimulation models used to evaluate the cost-effectiveness of novel cervical cancer screening technologies rely on accurate transition risks for human papillomavirus (HPV) infection, persistence (or absence of HPV clearance), progression to precancerous lesions, and invasion. To inform the refinement of such models, we compared the early natural history of HPV types using prospective data from immunocompetent women in the Guanacaste Natural History Study, the ASCUS-LSIL Triage Study, and the Costa Rica HPV Vaccine Trial. We…
Latin America & Caribbean | North America | Infectious Diseases | Mathematical Models | Microsimulation | Cost-Effectiveness Analysis -
ArticlePublication 2021Impact of COVID-19 on Cancer Diagnosis and Survival in Chile
This paper estimates the impact of the COVID-19 pandemic on delays in cancer diagnosis in …
This paper estimates the impact of the COVID-19 pandemic on delays in cancer diagnosis in Chile, using a microsimulation model of five cancers: breast, cervix, colorectal, prostate, and stomach. The model simulates cancer incidence and progression, as well as stage-specific cancer detection and survival probabilities, and was calibrated to empirical data on monthly detected cases, stage at diagnosis, and 5-year net survival. The analysis accounted for the impact of COVID-19 on month-by-month excess mortality and…
Latin America & Caribbean | Chronic Disease/Risk | Infectious Diseases | Health Outcomes | Microsimulation | Calibration/Validation -
ArticlePublication 2018Should We Treat Acute Hepatitis C? A Decision and Cost-Effectiveness Analysis
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared …
This study examines the potential benefits of treating acute hepatitis C virus (HCV) infection compared to deferring treatment until the chronic phase, utilizing a microsimulation model. By projecting long-term outcomes such as quality-adjusted life years (QALYs) and costs, the analysis evaluates the cost-effectiveness of initiating therapy during the acute phase. Results indicate that treating acute HCV increases QALYs by 0.02 and costs by $483 per patient not at risk of transmitting HCV, yielding an incremental…
North America | Chronic Disease/Risk | Infectious Diseases | Microsimulation | Decision Analysis | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2017Cost-Effectiveness of Testing and Treatment for Latent TB
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve …
Testing for and treating latent tuberculosis infection (LTBI) is among the main strategies to achieve TB elimination in the United States. This analysis estimated health outcomes, costs, and cost-effectiveness of LTBI testing and treatment among non-US born residents with and without medical comorbidities (e.g., diabetes, HIV infection, and end-stage renal disease). A decision analytic tree and Markov cohort simulation model was used to compare the following strategies: no testing, tuberculin skin test (TST), interferon gamma release assay…
North America | Chronic Disease/Risk | Infectious Diseases | Test Performance | State-Transition | Microsimulation | Cost-Effectiveness Analysis | Health Systems | Economics/Finance | Health/Medicine | Global -
ArticlePublication 2016Prevention of Hepatitis C by Screening and Treatment in U.S. Prisons
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and …
This study assesses the health and economic impact of hepatitis C virus (HCV) screening and treatment in U.S. prisons on the broader HCV epidemic. Employing an agent-based microsimulation model of HCV transmission and disease progression, data from published literature inform the analysis. The target populations include individuals in U.S. prisons and the general community over a 30-year timeframe, adopting a societal perspective. Interventions encompass risk-based and universal opt-out HCV screening in prisons, followed by treatment…
North America | Chronic Disease/Risk | Infectious Diseases | Microsimulation | Cost-Effectiveness Analysis | Health/Medicine -
ArticlePublication 2015Cost-Effectiveness & Budget Impact of Hepatitis C Virus Treatment with Sofosbuvir & Ledipasvir in the U.S.
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic …
This study evaluates the cost-effectiveness and budget impact of sofosbuvir and ledipasvir for treating chronic hepatitis C virus (HCV) infection compared to the old standard of care (oSOC). Using a microsimulation model based on HCV natural history, data from published literature, and a third-party payer perspective, the analysis considers treatment-naive and treatment-experienced HCV populations in the United States over a lifetime horizon. Sofosbuvir-based therapies are found to add 0.56 quality-adjusted life-years (QALYs) relative to oSOC,…
North America | Chronic Disease/Risk | Infectious Diseases | Microsimulation | Cost-Effectiveness Analysis | Health/Medicine -
ReviewPublication 2015Medicare's Use of CEA for Prevention (But Not Treatment)
Medicare currently pays for 23 preventive services in its benefits package, the majority of which …
Medicare currently pays for 23 preventive services in its benefits package, the majority of which were added since 2005. In the past decade, the program has transformed from one essentially administering treatment claims, to one increasingly focused on health promotion and maintenance. What is largely unappreciated is the role cost-effectiveness analysis has played in the coverage of preventive services. This study reviews the role of cost-effectiveness analysis in Medicare coverage of preventive services and contrast it…
North America | Chronic Disease/Risk | Infectious Diseases | Priority Setting/Ethics | Cost-Effectiveness Analysis | Technology Assessment | Child/Nutrition | Health Systems | Policy/Regulation | Economics/Finance | Government/Law | Health/Medicine -
ArticlePublication 2014Cost-Effectiveness of Female HPV Vaccination in 179 Countries: A PRIME Modelling Study
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), …
The authors present a simple generic model, Papillomavirus Rapid Interface for Modelling and Economics (PRIME), used to assess cost-effectiveness and health effects of vaccination of girls against HPV before sexual debut in terms of burden of cervical cancer and mortality. The PRIME models incidence according to proposed vaccine efficacy against HPV 16/18, vaccine coverage, cervical cancer incidence and mortality, and HPV type distribution. It assumes lifelong vaccine protection and no changes to other screening programs…
Latin America & Caribbean | Chronic Disease/Risk | Infectious Diseases | Health Outcomes | Mathematical Models | Calibration/Validation | Cost-Effectiveness Analysis | Health Systems | Health/Medicine | Global | Sub-Saharan Africa | Middle East & North Africa | Asia & Pacific